Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 7, 2009, Pages 1232-1233

  Peters, M J L ^a   Nurmohamed, M T ^a,b   Van Eijk, I C ^b   Verkleij, C J N ^c   Marx, P F ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN M; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENOTYPE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SERUM; BLOOD; INFLAMMATION; METABOLISM; MIDDLE AGED;

ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CARBOXYPEPTIDASE U; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 67549088271     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.097485     Document Type: Letter

References (8)

1. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
2. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
3. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002;22:867-73.
4. Juhan-Vague I, Morange PE. Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. J Thromb Haemost 2003;1:2243-4.
5. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002;88:1020-5.
6. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000;84:364-8.
7. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster JC, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003;1:2510-15.
8. Willemse JL, Leurs JR, Hendriks DF. Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma. J Thromb Haemost 2005;3:2353-5.